Dai Hong, Abdullah Razack, Wu Xiaoqiu, Li Fangfei, Ma Yuan, Lu Aiping, Zhang Ge
Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China.
Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China.
Front Cell Dev Biol. 2022 May 16;10:855474. doi: 10.3389/fcell.2022.855474. eCollection 2022.
Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.
胰腺癌（PC）是最致命的癌症之一，其5年生存率几乎为10%。由于胰腺癌具有高度异质性、促结缔组织增生性肿瘤微环境以及药物渗透效率低下等特点，目前推荐用于治疗胰腺癌的化疗策略临床获益有限。基于核酸的靶向治疗已成为药物研发和靶向治疗领域的有力竞争者。大量证据表明，基于抗体或适体的策略在很大程度上有助于提高肿瘤内的药物蓄积，同时降低全身细胞毒性。本文综述了反义寡核苷酸（ASO）、小干扰RNA（siRNA）、微小RNA（miRNA）、信使RNA（mRNA）和适体-药物偶联物（ApDC）在胰腺癌治疗中的研究进展，揭示了其在胰腺癌治疗中的广阔应用前景和发展方向。
